Skip to main content

Table 2 Transplant characteristics

From: Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT

Transplant characteristics RIC MAC p value
Number of patients 271 425  
Source of stem cells 0.001
 BM 95 (35.1 %) 202 (47.5 %)  
 PB 176 (64.9 %) 223 (52.5 %)  
Conditioning regimen  
 Chemotherapy-based 200 (73.8 %) 306 (72 %)  
 TBI-based 71 (26.2 %) 119 (28 %)  
In vivo T depletion 0.26
 Yes 140 (51.7 %) 201 (47.3 %)  
 Thymoglobulin 127 (91 %) 185 (92 %)
 Lymphoglobulin 2 (1 %) 1 (0.5 %)  
 Alemtuzumab 11 (8 %) 15 (7.5 %)  
 No 131 (48.3 %) 224 (52.7 %)
Post-transplant GVHD prophylaxis <0.0001
 CsA/FK506 + MMF or MTX 61 (23.2 %) 120 (30.3 %)  
 CsA + MMF + MTX 2 (0.8 %) 55 (13.9 %)  
 CsA + MMF + MTX + Basiliximab 19 (7.2 %) 40 (10.1 %)  
 PT-Cy + CsA/FK506 + MMF 66 (25.1 %) 125 (31.6 %)  
 Sirolimus + MMF 87 (33.1 %) 10 (2.5 %)  
 Other 28 (10.6 %) 46 (11.6 %)  
DLI    NS
 No DLI 247 (91.1 %) 389 (92.5 %)  
 Pre-emptive DLI 11 (4.1 %) 14 (3.3 %)  
 DLI after relapse 13 (4.8 %) 22 (5.2 %)  
  1. BM bone marrow, Bu busulfan, CSA cyclosporine, Cy cyclophosphamide, DLI donor lymphocyte injection, Flu fludarabine, MMF mycophenolate mofetyl, MTX methotrexate, PB peripheral blood, PT-CY post-transplant cyclophosphamide, TBI total body irradiation